Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Phase II Study of Intensified Adjuvant SHR-A1811 Versus Trastuzumab Plus Pertuzumab in Patients With Initially Stage IIB-IIIC HER2-Positive Early Breast Cancer Who Achieved Pathologic Complete Response After Neoadjuvant Therapy and Have Postoperative ctDNA Positivity

NCT07856303 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07856303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07856303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Phase II Study of Intensified Adjuvant SHR-A1811 Versus Trastuzumab Plus Pertuzumab in Patients With Initially Stage IIB-IIIC HER2-Positive Early Breast Cancer Who Achieved Pathologic Complete Response After Neoadjuvant Therapy and Have Postoperative ctDNA Positivity
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
August 31, 2034
Enrollment
358 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

early breast cancer (ebc), her2-positive breast cancer